Previous Close | 15.13 |
Open | 15.05 |
Bid | 15.60 x 1400 |
Ask | 15.84 x 2200 |
Day's Range | 15.02 - 15.14 |
52 Week Range | 13.48 - 15.86 |
Volume | |
Avg. Volume | 200,640 |
Market Cap | 819.956M |
Beta (5Y Monthly) | 1.12 |
PE Ratio (TTM) | 10.74 |
EPS (TTM) | 1.40 |
Earnings Date | May 08, 2024 - May 13, 2024 |
Forward Dividend & Yield | 1.64 (10.91%) |
Ex-Dividend Date | Mar 13, 2024 |
1y Target Est | 15.63 |
Subscribe to Yahoo Finance Plus to view Fair Value for SLRC
Net Investment Income Grows as Company Capitalizes on Favorable Investment Environment
Net Investment Income of $0.44 Per Share for Q4 2023; Declared Quarterly Distribution of $0.41 Per Share; Stable NAV and Strong Portfolio Credit Quality NEW YORK, Feb. 27, 2024 (GLOBE NEWSWIRE) -- SLR Investment Corp. (NASDAQ: SLRC) (the “Company”, “SLRC”, “we”, or “our”) today reported net investment income of $23.9 million, or $0.44 per share, for the fourth quarter of 2023. As of December 31, 2023, net asset value (NAV) was $18.09 per share, compared to $18.06 as of September 30, 2023. In the
CLEVELAND, Feb. 01, 2024 (GLOBE NEWSWIRE) -- SPR Therapeutics, a private medical device company focused on treating pain and improving the quality of life for patients managing acute or chronic pain, today announced that it has secured $85 million in financing including $25 million in Series D-1 insider equity and a $60 million debt facility. The equity financing was led by Revelation Partners, SPR’s lead investor of the Series D equity financing, and incumbent investors, RC Capital and Mutual C